Buprenorphine

Major

Buprenorphine Cobicistat Tybost Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Cocaine Goprelto Explained An increased risk of serotonin syndrome Details Buprenorphine Codeine Tuzistra XR® (as a combination product containing Chlorpheniramine, Codeine) Explained Reduced analgesic effect and/or precipitation of withdrawal symptoms, an increased risk of serotonin syndrome and an increased ris... Details Buprenorphine Conivaptan Vaprisol Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Crizotinib Xalkori Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Cyclobenzaprine Amrix Explained An increased risk of serotonin syndrome, an increased risk of QT interval prolongation, an increased risk of CNS and respiratory d... Details Buprenorphine Cyclopenthiazide Explained Reduced efficacy of diuretics Details Buprenorphine Cyclopentolate Cyclogyl Explained An increased risk of paralytic ileus Details Buprenorphine Cyclosporine Atopica Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Cyclothiazide Explained Reduced efficacy of diuretics Details Buprenorphine Cyproheptadine Explained An increased risk of paralytic ileus and an increased risk of CNS depression Details Buprenorphine Dabrafenib Tafinlar Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Buprenorphine Dantrolene Dantrium Explained Enhanced neuromuscular blocking action and an increased risk of respiratory depression and CNS depression Details Buprenorphine Daridorexant Explained An increased risk CNS depression Details Buprenorphine Darifenacin Enablex Explained An increased risk of paralytic ileus Details Buprenorphine Darunavir Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Dasatinib Phyrago An increased risk of QT interval prolongation Details Buprenorphine Degarelix Firmagon Explained An increased risk of QT interval prolongation Details Buprenorphine Delamanid Explained An increased risk of QT interval prolongation Details Buprenorphine Delavirdine Rescriptor® Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Delorazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Desflurane Suprane Explained An increased risk of QT interval prolongation, reduced desflurane (MAC) exposure needed to produce anesthesia Details Buprenorphine Desipramine Norpramin Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Deslorelin Explained An increased risk of QT interval prolongation Details Buprenorphine Desvenlafaxine Pristiq Explained An increased risk of serotonin syndrome Details Buprenorphine Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Buprenorphine Dexamethasone Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Dexmedetomidine Dexased Explained Increased risk of cardiac arrhythmias and increased risk of CNS depression Details Buprenorphine Dextroamphetamine Dexedrine Explained An increased risk of serotonin syndrome Details Buprenorphine Dextromethorphan Delsym Explained An increased risk of serotonin syndrome Details Buprenorphine Dezocine Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome and respiratory depr... Details Buprenorphine Diacetylmorphine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Diazepam Diastat Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Diazoxide Proglycem Explained Reduced efficacy of diuretics Details Buprenorphine Dibenzepin Explained An increased risk of serotonin syndrome Details Buprenorphine Dichloralphenazone Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Dicyclomine Bentyl Explained An increased risk of paralytic ileus Details Buprenorphine Difenoxin Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Dihydrocodeine Explained Reduced analgesic effect or precipitation of withdrawal symptoms and an increased risk of serotonin syndrome Details Buprenorphine Diltiazem Cardizem Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details